Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evinacumab - Regeneron Pharmaceuticals

Next Previous
X
Search
Drug Profile

Evinacumab - Regeneron Pharmaceuticals

Alternative Names: Evinacumab-dgnb; Evkeeza; REGN-1500

Latest Information Update: 22 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Developer Regeneron Pharmaceuticals; Ultragenyx Pharmaceutical
  • Class Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action ANGPTL3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type II
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperlipoproteinaemia type II
  • Phase II Hypertriglyceridaemia

Most Recent Events

  • 15 Jul 2024 Regeneron Pharmaceuticals plans an expanded access trial for Hypertriglyceridemia, Hyperlipoproteinaemia-type-III and Hypercholesterolemia (Unspecified) (NCT06500598)
  • 18 Jan 2024 Registered for Hyperlipoproteinaemia type II in Japan (IV) - First global approval
  • 04 Jan 2024 Launched for Hyperlipoproteinaemia type II (In adolescents, In children, In the elderly, In adults, Adjunctive treatment) in Germany, Canada, United Kingdom, Italy (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top